Poster Presentation: Where Does Your Therapy Go—and Where Does It Make a Difference? Connecting Tissue Biodistribution to Biological Response in Gene Therapy Development
04 Nov 2026
Gene Therapy Development
- What are the advantages of assessing spatial biodistribution of analytes versus other approaches such as tissue homogenization and LC-MS?
- In the AmberGen approach, what Omics layers / analytes can be regionally quantified (i.e. reporting analyte concentration in a region) versus only relative quantification?
- How can we tell whether a therapy is reaching the cells we want to target, rather than simply reaching the organ?
- What is the advantage of this approach versus others, for example versus Visium from 10x Genomics?
- How can the AmberGen methods be used to understand why a therapy works in one part of the anatomy but not others?
- Where in a development program would this information be most useful, and what decisions could it help us make?
Industry Expert
